
AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of…
PARIS, France, December 14th 2020 (BUSINESS WIRE)
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
Lire la suite de « AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01 »“I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Stéphane Thiroloix, Founder & CEO of AlgoTherapeutix